Vanda Pharmaceuticals (VNDA) Equity Average (2011 - 2026)

Vanda Pharmaceuticals has disclosed Equity Average across 16 years of filings, most recently posting $304.0 million for Q1 2026.

• Equity Average for Q1 2026 came in at $304.0 million, down 42.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $304.0 million (down 42.1% YoY), and the FY2025 annual result was $432.9 million, down 20.1% from the prior year.
• Equity Average came in at $304.0 million for Q1 2026 at Vanda Pharmaceuticals, down from $396.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $544.5 million in Q1 2024 to a low of $304.0 million in Q1 2026.
• The 5-year median for Equity Average is $525.0 million (2025), against an average of $504.0 million.
• Across the five-year window, Equity Average climbed 9.36% in 2022 and slumped 42.1% in 2026, its largest moves.
• Vanda Pharmaceuticals' Equity Average stood at $521.4 million in 2022, then climbed by 4.33% to $544.0 million in 2023, then slipped by 0.76% to $539.9 million in 2024, then declined by 26.54% to $396.6 million in 2025, then declined by 23.35% to $304.0 million in 2026.
• The last three Equity Average figures came in at $304.0 million (Q1 2026), $396.6 million (Q4 2025), and $476.2 million (Q3 2025), per Business Quant data.